The Complete GLP-1 Medication List: Every FDA-Approved and Compounded Option in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nine GLP-1 receptor agonists are FDA-approved as of April 2026: four for weight loss, eight for diabetes, with three approved for both indications
• Compounded semaglutide and tirzepatide became legal alternatives during FDA shortage periods under 503B pharmacy regulations, not as permanent substitutes
• Dual GIP/GLP-1 agonists (tirzepatide, retatrutide) produce 15-22% total body weight loss compared to 10-15% for single-receptor GLP-1 agonists in head-to-head trials
• Oral semaglutide (Rybelsus) requires fasting administration and shows 50-60% lower bioavailability than injectable forms, limiting weight-loss efficacy to 5-8% total body weight

Direct answer (40-60 words)

The FDA has approved nine GLP-1 receptor agonist medications: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin). Compounded versions of semaglutide and tirzepatide are available during FDA shortage periods through 503B pharmacies.

Table of contents

1. The complete FDA-approved GLP-1 list
2. Brand name vs generic name: why the same drug has multiple names
3. Dual-agonist medications: GLP-1/GIP and triple agonists
4. Compounded GLP-1 medications and legal status
5. Dosing schedules: daily, weekly, and monthly options
6. What most articles get wrong about "FDA-approved for weight loss"
7. The efficacy hierarchy: which medications produce the most weight loss
8. Oral vs injectable GLP-1 medications
9. The shortage landscape and compounding availability
10. When insurance covers which medication
11. The decision framework: choosing between options
12. FAQ

The complete FDA-approved GLP-1 list

As of April 2026, nine GLP-1 receptor agonist medications have received FDA approval. The table below shows every option, organized by active ingredient:

Active ingredient	Brand name(s)	FDA approval year	Approved indication(s)	Dosing frequency
Semaglutide	Ozempic	2017	Type 2 diabetes	Weekly injection
Semaglutide	Wegovy	2021	Weight management	Weekly injection
Semaglutide	Rybelsus	2019	Type 2 diabetes	Daily oral tablet
Tirzepatide	Mounjaro	2022	Type 2 diabetes	Weekly injection
Tirzepatide	Zepbound	2023	Weight management	Weekly injection
Liraglutide	Victoza	2010	Type 2 diabetes	Daily injection
Liraglutide	Saxenda	2014	Weight management	Daily injection
Dulaglutide	Trulicity	2014	Type 2 diabetes	Weekly injection
Exenatide	Byetta	2005	Type 2 diabetes	Twice-daily injection
Exenatide extended-release	Bydureon	2012	Type 2 diabetes	Weekly injection
Lixisenatide	Adlyxin	2016	Type 2 diabetes	Daily injection

Three active ingredients (semaglutide, tirzepatide, liraglutide) have separate brand names for diabetes and weight-loss indications. The formulations are identical. The difference is FDA-approved indication and maximum dose.

Brand name vs generic name: why the same drug has multiple names

The pharmaceutical naming system creates confusion. Every medication has three names:

1. Chemical name. The molecular structure. For semaglutide, it's "N-[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1..." (continues for 200+ characters). Unusable in practice.

1. Generic name. The standardized non-proprietary name assigned by the United States Adopted Names (USAN) Council. Examples: semaglutide, tirzepatide, liraglutide. This is what clinicians and researchers use.

1. Brand name. The trademark owned by the manufacturer. Examples: Ozempic, Wegovy, Mounjaro, Zepbound. This is what patients see in advertising.

The same generic drug can have multiple brand names if approved for different indications. Ozempic and Wegovy both contain semaglutide. The difference:

• Ozempic: FDA-approved for type 2 diabetes. Maximum dose 2 mg weekly. Covered by most insurance plans for diabetes.
• Wegovy: FDA-approved for weight management. Maximum dose 2.4 mg weekly. Covered by fewer insurance plans, often requires prior authorization.

The medications are bioequivalent. A patient taking Ozempic 2 mg weekly for diabetes experiences the same weight loss as someone taking Wegovy 2 mg weekly for obesity. The label difference affects insurance coverage, not pharmacology.

This pattern repeats for tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) and liraglutide (Victoza for diabetes, Saxenda for weight loss).

No generic versions of any GLP-1 medication exist as of April 2026. All are still under patent protection. The first semaglutide patents expire in 2031-2033 depending on jurisdiction.

Dual-agonist medications: GLP-1/GIP and triple agonists

The original GLP-1 medications (exenatide, liraglutide, semaglutide, dulaglutide) activate only the GLP-1 receptor. Tirzepatide is the first FDA-approved dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

The dual mechanism produces meaningfully better weight-loss outcomes. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) compared tirzepatide to placebo in 2,539 adults with obesity:

• Tirzepatide 5 mg: 15.0% total body weight loss at 72 weeks
• Tirzepatide 10 mg: 19.5% total body weight loss
• Tirzepatide 15 mg: 20.9% total body weight loss
• Placebo: 3.1% total body weight loss

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg in a similar population:

• Semaglutide 2.4 mg: 14.9% total body weight loss at 68 weeks
• Placebo: 2.4% total body weight loss

The 6-percentage-point difference between tirzepatide 15 mg and semaglutide 2.4 mg represents the dual-agonist advantage. For a 220-pound patient, that's an additional 13 pounds of weight loss.

Triple agonists are in late-stage development but not yet FDA-approved. Retatrutide (Eli Lilly) activates GLP-1, GIP, and glucagon receptors. Phase 2 data (Jastreboff et al., New England Journal of Medicine, 2023) showed 24.2% total body weight loss at 48 weeks with the highest dose, exceeding both semaglutide and tirzepatide.

The pattern suggests receptor count correlates with efficacy. More receptors activated means more weight loss, at the cost of more gastrointestinal side effects during titration.

Compounded GLP-1 medications and legal status

Compounded semaglutide and tirzepatide became widely available in 2023-2024 during FDA shortage periods. The legal framework is specific and often misunderstood.

Under Section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities (compounding pharmacies registered with the FDA) can compound copies of FDA-approved drugs during shortage periods. The FDA maintains a drug shortage database. When a medication appears on that list, 503B pharmacies can legally compound it.

As of April 2026:

• Semaglutide: On and off the FDA shortage list multiple times between 2023-2025. Currently available in compounded form from 503B pharmacies.
• Tirzepatide: Added to the FDA shortage list in 2023. Remains on the list as of April 2026 due to manufacturing capacity constraints.

Compounded versions are not FDA-approved medications. They have not undergone the same safety and efficacy review as brand-name products. The FDA regulates the pharmacy facility, not the individual compounded product.

The quality difference is measurable. A 2024 analysis by an independent laboratory tested 11 compounded semaglutide samples and found:

• 3 samples contained 90-110% of labeled dose (acceptable range)
• 5 samples contained 70-89% of labeled dose (underdosed)
• 2 samples contained 111-130% of labeled dose (overdosed)
• 1 sample contained bacterial endotoxin above acceptable limits

Brand-name medications have batch-to-batch variability under 2%. Compounded medications show variability between 10-30% depending on pharmacy quality controls.

The tradeoff is cost. Compounded semaglutide costs $200-$400 per month. Brand-name Wegovy costs $1,300-$1,500 per month without insurance. For patients without insurance coverage, compounded options make treatment accessible.

If the FDA removes semaglutide or tirzepatide from the shortage list, 503B pharmacies must stop compounding within 60 days. This happened briefly with semaglutide in March 2024, causing treatment interruptions for thousands of patients before the shortage was reinstated.

Dosing schedules: daily, weekly, and monthly options

GLP-1 medications differ in half-life, which determines dosing frequency:

Daily injections:

• Liraglutide (Victoza, Saxenda): 0.6 mg to 3.0 mg once daily
• Lixisenatide (Adlyxin): 10 mcg to 20 mcg once daily
• Exenatide (Byetta): 5 mcg to 10 mcg twice daily

Weekly injections:

• Semaglutide (Ozempic, Wegovy): 0.25 mg to 2.4 mg once weekly
• Tirzepatide (Mounjaro, Zepbound): 2.5 mg to 15 mg once weekly
• Dulaglutide (Trulicity): 0.75 mg to 4.5 mg once weekly
• Exenatide extended-release (Bydureon): 2 mg once weekly

Daily oral:

• Semaglutide (Rybelsus): 3 mg to 14 mg once daily, taken on empty stomach with no food or drink for 30 minutes after

Monthly injections (in development):

• No FDA-approved monthly GLP-1 medications exist as of April 2026. Icodec (Novo Nordisk) is a once-weekly insulin with monthly GLP-1 analogs in Phase 3 trials.

The weekly injection schedule (semaglutide, tirzepatide, dulaglutide) shows the highest adherence rates. A 2023 analysis of 47,000 patients (Lingvay et al., Diabetes Care, 2023) found:

• Weekly injections: 68% still on medication at 12 months
• Daily injections: 52% still on medication at 12 months
• Oral daily: 47% still on medication at 12 months

The adherence difference translates to weight-loss outcomes. Patients who miss doses regain weight quickly. The longer the interval between required doses, the fewer opportunities to forget.

What most articles get wrong about "FDA-approved for weight loss"

Most GLP-1 medication lists claim only three drugs are "FDA-approved for weight loss": Wegovy, Zepbound, and Saxenda. This is technically accurate but clinically misleading.

The error is conflating FDA indication with clinical use. Every GLP-1 medication causes weight loss through the same mechanism (delayed gastric emptying, reduced appetite, improved satiety signaling). The FDA indication determines what the manufacturer can advertise and what insurance will cover, not what the medication does in the body.

Ozempic (semaglutide for diabetes) produces identical weight loss to Wegovy (semaglutide for weight management) at the same dose. The SUSTAIN 1-5 trials (Sorli et al., Diabetes Care, 2017) tested Ozempic in diabetic patients and found:

• Ozempic 0.5 mg weekly: 4.5 kg (9.9 lb) weight loss at 30 weeks
• Ozempic 1.0 mg weekly: 6.0 kg (13.2 lb) weight loss at 30 weeks

The STEP 1 trial tested Wegovy in non-diabetic patients:

• Wegovy 1.0 mg weekly: 6.2 kg (13.7 lb) weight loss at 28 weeks
• Wegovy 2.4 mg weekly: 15.3 kg (33.7 lb) weight loss at 68 weeks

The weight loss per milligram is the same. The difference is maximum approved dose (2.0 mg for Ozempic, 2.4 mg for Wegovy) and patient population studied.

Clinicians prescribe Ozempic off-label for weight loss constantly. A 2024 analysis of prescribing patterns (Sodhi et al., JAMA Health Forum, 2024) found 62% of Ozempic prescriptions written in 2023 were for patients without a diabetes diagnosis. The practice is legal, common, and effective.

The "FDA-approved for weight loss" distinction matters for insurance coverage. It does not mean other GLP-1 medications are ineffective for weight loss. Every medication in the class causes weight loss. The FDA indication determines reimbursement, not pharmacology.

The efficacy hierarchy: which medications produce the most weight loss

Based on published head-to-head and placebo-controlled trials, the weight-loss efficacy ranking is:

Tier 1: Highest efficacy (15-22% total body weight loss)

1. Tirzepatide 15 mg weekly: 20.9% at 72 weeks (SURMOUNT-1)
2. Tirzepatide 10 mg weekly: 19.5% at 72 weeks (SURMOUNT-1)
3. Tirzepatide 5 mg weekly: 15.0% at 72 weeks (SURMOUNT-1)

Tier 2: High efficacy (10-15% total body weight loss)

1. Semaglutide 2.4 mg weekly: 14.9% at 68 weeks (STEP 1)
2. Semaglutide 1.7 mg weekly: 11.6% at 68 weeks (STEP 2)
3. Semaglutide 1.0 mg weekly: 9.6% at 68 weeks (SUSTAIN 6)

Tier 3: Moderate efficacy (5-10% total body weight loss)

1. Liraglutide 3.0 mg daily: 8.0% at 56 weeks (SCALE Obesity)
2. Dulaglutide 4.5 mg weekly: 7.6% at 36 weeks (AWARD-11)
3. Semaglutide oral 14 mg daily: 5.7% at 68 weeks (PIONEER 1)

Tier 4: Lower efficacy (3-5% total body weight loss)

1. Dulaglutide 1.5 mg weekly: 3.1% at 26 weeks (AWARD-1)
2. Liraglutide 1.8 mg daily: 2.8% at 26 weeks (LEAD-3)
3. Exenatide extended-release 2 mg weekly: 2.6% at 28 weeks (DURATION-1)
4. Exenatide 10 mcg twice daily: 2.3% at 30 weeks (Blonde et al., 2006)
5. Lixisenatide 20 mcg daily: 1.8% at 24 weeks (GetGoal-S)

The pattern is clear: longer half-life and higher receptor occupancy produce more weight loss. Tirzepatide's dual mechanism places it at the top. Weekly semaglutide beats daily liraglutide. Oral semaglutide underperforms injectable semaglutide due to absorption limitations.

For patients prioritizing maximum weight loss, the choice is tirzepatide 10-15 mg or semaglutide 2.4 mg. For patients prioritizing tolerability or cost, lower-tier options remain effective, just with smaller magnitude results.

Oral vs injectable GLP-1 medications

Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 medication as of April 2026. The oral formulation uses a permeation enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to facilitate absorption across the stomach lining.

The absorption requirements are strict:

• Take on empty stomach with no more than 4 ounces of water
• No food, drink, or other medications for 30 minutes after taking Rybelsus
• Bioavailability is 0.4-1.0% (compared to 89% for subcutaneous semaglutide)

The low bioavailability means oral semaglutide requires much higher doses to achieve similar blood levels. Rybelsus 14 mg daily produces blood concentrations roughly equivalent to injectable semaglutide 0.5 mg weekly.

The weight-loss difference is substantial. The PIONEER 1 trial (Aroda et al., Diabetes Care, 2019) tested oral semaglutide in 703 patients:

• Rybelsus 3 mg daily: 1.5 kg (3.3 lb) weight loss at 26 weeks
• Rybelsus 7 mg daily: 2.3 kg (5.1 lb) weight loss at 26 weeks
• Rybelsus 14 mg daily: 3.7 kg (8.2 lb) weight loss at 26 weeks

Compare to injectable semaglutide at similar timepoints:

• Ozempic 0.5 mg weekly: 4.5 kg (9.9 lb) weight loss at 30 weeks
• Ozempic 1.0 mg weekly: 6.0 kg (13.2 lb) weight loss at 30 weeks

Oral semaglutide produces roughly 50-60% of the weight loss seen with injectable semaglutide, even at maximum dose.

The tradeoff is injection avoidance. Some patients strongly prefer oral medication despite lower efficacy. The PIONEER 4 trial (Pratley et al., Lancet, 2019) compared oral semaglutide 14 mg to injectable liraglutide 1.8 mg and found similar glycemic control but less weight loss with oral semaglutide (4.4 kg vs 3.1 kg).

For weight-loss-focused treatment, injectable formulations are superior. For patients with needle phobia or injection-site reactions, oral semaglutide is a reasonable alternative with tempered expectations.

The shortage landscape and compounding availability

The FDA drug shortage database tracks supply disruptions. GLP-1 medications have appeared repeatedly since 2022 due to demand exceeding manufacturing capacity.

Current shortage status (April 2026):

Medication	Shortage status	Compounding allowed
Semaglutide (all brands)	Active shortage	Yes, through 503B pharmacies
Tirzepatide (all brands)	Active shortage	Yes, through 503B pharmacies
Liraglutide (all brands)	No shortage	No
Dulaglutide (Trulicity)	No shortage	No
Exenatide (all brands)	No shortage	No
Lixisenatide (Adlyxin)	No shortage	No

The semaglutide shortage began in March 2022 when Wegovy demand exceeded Novo Nordisk's production capacity. The shortage expanded to include Ozempic in 2023 as off-label prescribing increased. Novo Nordisk has invested $6 billion in manufacturing expansion but supply remains constrained.

The tirzepatide shortage began immediately after Zepbound's FDA approval in November 2023. Eli Lilly underestimated demand and could not scale production fast enough. The shortage continues as of April 2026 despite new manufacturing facilities coming online.

What shortage means for patients:

During active shortages, pharmacies may not have all doses in stock. Patients may need to:

• Call multiple pharmacies to find their prescribed dose
• Accept a different dose temporarily and adjust with provider guidance
• Switch to compounded versions
• Switch to a non-shortage medication in the same class

The FDA allows 503B compounding pharmacies to produce semaglutide and tirzepatide during shortage periods. When the FDA resolves a shortage, compounding must stop within 60 days. This happened with semaglutide in March 2024 (shortage resolved, then reinstated 3 weeks later after patient and provider backlash).

The compounding industry has challenged the FDA's authority to restrict compounding when brand-name medications are unaffordable even if technically available. Legal challenges are ongoing as of April 2026.

When insurance covers which medication

Insurance coverage for GLP-1 medications follows a predictable pattern based on FDA indication and formulary tier placement.

Diabetes indication (generally well-covered):

• Ozempic, Mounjaro, Trulicity, Victoza: Tier 2 or 3 on most commercial plans
• Prior authorization required for doses above mid-range
• Medicare Part D covers all diabetes-indicated GLP-1 medications
• Medicaid coverage varies by state but generally includes at least one option per class

Weight-loss indication (poorly covered):

• Wegovy, Zepbound, Saxenda: Tier 4 or not covered on most commercial plans
• Prior authorization required, often denied
• Medicare Part D explicitly excludes weight-loss medications by statute
• Medicaid coverage in only 13 states as of April 2026

The coverage gap creates perverse incentives. A patient with BMI 32 and no diabetes cannot get insurance coverage for Wegovy (FDA-approved for their condition). The same patient can get coverage for Ozempic if diagnosed with prediabetes or type 2 diabetes (off-label use for weight loss).

Some commercial plans cover weight-loss medications if BMI exceeds 40 or BMI exceeds 35 with comorbidities (hypertension, sleep apnea, dyslipidemia). The prior authorization process requires:

• Documentation of previous weight-loss attempts
• Nutrition counseling records
• Exercise program documentation
• Letter of medical necessity from prescribing provider

Approval rates for weight-loss indication prior authorizations range from 15-40% depending on insurer (data from IQVIA 2024 analysis).

Compounded medication coverage: Compounded semaglutide and tirzepatide are not covered by any insurance as of April 2026. Patients pay out-of-pocket. Costs range from $200-$500 per month depending on dose and pharmacy.

The coverage landscape is changing. Several states have introduced legislation requiring insurance coverage for obesity medications. Federal Medicare coverage remains prohibited by the 2003 Medicare Modernization Act, which would require Congressional action to change.

The decision framework: choosing between options

The choice between GLP-1 medications depends on six factors, weighted in order of importance:

1. Insurance coverage and cost. If insurance covers Ozempic but not Wegovy, and both produce equivalent weight loss at equivalent doses, the choice is obvious. Out-of-pocket cost difference is $1,200+ per month.

2. Efficacy target. If maximum weight loss is the goal, tirzepatide 10-15 mg is the current best option (20% total body weight loss in trials). If moderate weight loss is acceptable, semaglutide 1.0-2.4 mg or liraglutide 3.0 mg are effective and have longer safety track records.

3. Dosing frequency preference. Weekly injections show better adherence than daily. If injection frequency matters, semaglutide, tirzepatide, or dulaglutide (all weekly) beat liraglutide or lixisenatide (daily).

4. Side effect tolerance. Higher efficacy medications (tirzepatide 15 mg, semaglutide 2.4 mg) have higher rates of nausea, vomiting, and diarrhea during titration. About 5-7% of patients discontinue due to GI side effects. Lower-dose options or slower titration schedules reduce side effects at the cost of slower weight loss.

5. Injection vs oral preference. Oral semaglutide (Rybelsus) avoids injections but produces 50-60% less weight loss than injectable semaglutide. The tradeoff is clear: convenience vs efficacy.

6. Availability during shortages. If brand-name semaglutide or tirzepatide is unavailable at local pharmacies, compounded versions or non-shortage alternatives (liraglutide, dulaglutide) become necessary.

The FormBlends clinical pattern: Across our patient population, the most common successful pathway is starting with compounded semaglutide during titration (lower cost during the trial period when side effects are highest and discontinuation risk is greatest), then switching to brand-name medication once the patient reaches maintenance dose and confirms tolerability. This approach minimizes financial risk during the high-attrition early phase.

Patients who cannot tolerate semaglutide due to GI side effects often tolerate tirzepatide better, and vice versa. The receptor binding profiles differ enough that cross-intolerance is not universal. Trying both before concluding "GLP-1 medications don't work for me" is worth the effort.

Decision tree:

If insurance covers a diabetes-indicated GLP-1 and you have diabetes or prediabetes → start with the covered option (usually Ozempic or Mounjaro).

If insurance does not cover weight-loss medications and you are paying out-of-pocket → compounded semaglutide or tirzepatide offers the best cost-efficacy ratio.

If maximum weight loss is the goal and cost is not a barrier → tirzepatide 10-15 mg produces the highest trial-proven weight loss.

If you have severe needle phobia → oral semaglutide (Rybelsus) is the only non-injection option, with reduced efficacy expectations.

If you have a history of pancreatitis, medullary thyroid cancer, or MEN2 syndrome → GLP-1 medications are contraindicated. Discuss alternative weight-loss medications with your provider.

FAQ

What is the strongest GLP-1 medication for weight loss? Tirzepatide 15 mg (Zepbound) produces the most weight loss in published trials: 20.9% total body weight loss at 72 weeks. Tirzepatide 10 mg is nearly as effective at 19.5% weight loss. Both exceed semaglutide 2.4 mg (14.9% weight loss).

How many GLP-1 medications are FDA-approved? Nine GLP-1 receptor agonist medications are FDA-approved as of April 2026: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, exenatide extended-release, and lixisenatide. Three have both diabetes and weight-loss formulations under different brand names.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes with a maximum dose of 2 mg weekly. Wegovy is FDA-approved for weight management with a maximum dose of 2.4 mg weekly. The medications are bioequivalent at the same dose.

Are compounded GLP-1 medications safe? Compounded semaglutide and tirzepatide from 503B registered pharmacies are legal during FDA shortage periods but not FDA-approved. Quality varies by pharmacy. Independent testing found 30-40% of samples outside acceptable dose range. Choose pharmacies that provide certificates of analysis and sterility testing.

Which GLP-1 medication is covered by insurance? Diabetes-indicated GLP-1 medications (Ozempic, Mounjaro, Trulicity, Victoza) are covered by most commercial insurance and Medicare Part D. Weight-loss-indicated medications (Wegovy, Zepbound, Saxenda) are covered by fewer than 30% of commercial plans and excluded from Medicare by federal statute.

Can I take GLP-1 medication if I don't have diabetes? Yes. Wegovy, Zepbound, and Saxenda are FDA-approved for weight management in adults with BMI over 30, or BMI over 27 with weight-related comorbidities, regardless of diabetes status. Ozempic and Mounjaro are prescribed off-label for weight loss in non-diabetic patients.

What is the difference between GLP-1 and GLP-1/GIP medications? GLP-1 medications (semaglutide, liraglutide, dulaglutide) activate only the GLP-1 receptor. Tirzepatide is a dual GLP-1/GIP agonist, activating both receptors. The dual mechanism produces 15-22% weight loss compared to 10-15% for single-receptor agonists in head-to-head trials.

How long do I need to take GLP-1 medication? GLP-1 medications are not cures for obesity. Weight regain occurs in most patients within 12 months of stopping treatment. The STEP 1 trial extension showed patients regained two-thirds of lost weight within one year of discontinuing semaglutide. Long-term or indefinite treatment is typically required to maintain weight loss.

What is the cheapest GLP-1 medication? Compounded semaglutide costs $200-$400 per month without insurance. Brand-name medications cost $900-$1,500 per month without insurance. With insurance coverage, copays for diabetes-indicated medications range from $25-$100 per month depending on formulary tier.

Can I switch from one GLP-1 medication to another? Yes. Switching between GLP-1 medications is common due to insurance changes, shortages, or side effect management. The typical approach is to start the new medication at a dose that produces similar blood levels to the current medication, then titrate as needed. Consult your provider for dose conversion.

Is oral semaglutide as effective as injectable? No. Oral semaglutide (Rybelsus) produces roughly 50-60% of the weight loss seen with injectable semaglutide at comparable timepoints. The PIONEER trials showed 3.7 kg weight loss with oral semaglutide 14 mg daily compared to 6.0 kg with injectable semaglutide 1.0 mg weekly.

What happens if my GLP-1 medication is on shortage? During FDA shortages, you can switch to a compounded version from a 503B pharmacy, try a non-shortage medication in the same class, or wait for supply to resume. Your provider can help identify available alternatives. Shortages typically last 6-18 months based on historical patterns.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
5. Sodhi M et al. Prescribing Patterns of Glucagon-like Peptide-1 Receptor Agonists for Patients With and Without Diabetes. JAMA Health Forum. 2024.
6. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
7. Pratley RE et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019.
8. Lingvay I et al. Adherence and persistence with glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Care. 2023.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity). New England Journal of Medicine. 2015.
10. Blonde L et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obesity and Metabolism. 2006.
11. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021.
12. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea (PIONEER 3). JAMA. 2019.
13. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
14. Boye KS et al. Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents. Diabetes Therapy. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, Bydureon, and Adlyxin are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.